Figure 1From: Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays Kaplan-Meyer curve showing progression-free survival (PFS) of patients with (green line) or without (blue line) activating EGFR mutations identified in the plasma DNA. The group with activating EGFR mutations has a significantly longer PFS than the group without these mutations, with a p-value of 0.01.Back to article page